Argireline: what the evidence shows

What the human research shows

A cosmetic ingredient with one small, short, positive randomised trial behind it — and a publication record that makes the literature look three times larger than it is. Graded C: real randomised human data, far too little of it to call the effect established, and nothing at all comparable to the injectable it is marketed against.

Evidence profile0–5

Metabolic & weight—0.0
Cardiovascular—0.0
Muscle & growth—0.0
Healing & repair—0.0
Neuro & sleep—0.0
Immune & inflammation—0.0
Sexual & hormonal—0.0
Skin & appearanceC0.7
Ageing & longevity—0.0

Each score is confidence × effect size, taken from the best-evidenced benefit in that domain: the grade (A–D) sets the confidence, the measured effect sets the size. Hover a domain to see the outcomes behind it. Adverse effects are excluded and listed separately below.

Outcome	Grade	Effect size	Human studies	Where the evidence comes from
Periorbital wrinkles and skin roughness (topical)	CWeak	Small	1 RCT (n=60, 4 wk)	A Chinese randomised, placebo-controlled trial applied a 10% argireline solution twice daily around the eyes in 60 people for four weeks, randomised 3:1. Objective roughness parameters fell in the treated group and not on placebo, and the investigators' subjective rating gave 48.9% total anti-wrinkle efficacy against 0%. Four weeks, 60 people, one centre, and the same dataset was published three times.1 2
Subjective wrinkle improvement (topical)	CWeak	Small	1 RCT (n=60, 4 wk)	The subjective arm of the same trial. A 48.9%-versus-0% split is a large number from a small unreplicated study, and subjective grading in a topical trial is the endpoint most sensitive to expectation.1
Comparison with botulinum toxin	DNo human evidence	Not measurable	None	No trial has compared argireline with botulinum toxin injections. The marketing comparison rests on a shared molecular target in vitro, not on any head-to-head result.
Safety (topical)adverse	CWeak	Not measurable	1 RCT (n=60)	No adverse effects were reported in the four-week trial, consistent with its long use as a cosmetic ingredient. Four weeks in 60 people is a weak basis for a safety claim, though a topically applied hexapeptide is a low-risk proposition.1

AMultiple good human trials, consistentBSome human trials, mostly consistentCFew or weak human studiesDAnimal or anecdotal onlyeffect size · red = adverse

Literature searched to 29 October 2026. Human studies only; animal and cell work informs the mechanism section and nothing else.

Registered trials

ClinicalTrials.gov lists 1 interventional study naming Argireline as an intervention, and 1 with results posted to the registry.

A registration is not a result. Anyone can register a study, and many never report — so this list shows what has been attempted, not what has been shown. The graded evidence above is the answer to whether something works.

Study	Phase	Status	Participants	Sponsor	Results
Acetyl Hexapeptide-8 for BlepharospasmNCT01750346 · started Nov 2012	Phase 2	Terminated	8	National Institute of Neurological Disorders and Stroke (NINDS)	Posted

Participant counts marked * are the sponsor's estimate, not a final enrolment. Source: ClinicalTrials.gov, read directly from the registry and refreshed weekly.

What it is

Argireline is the trade name Lipotec gave to acetyl hexapeptide-8, a six-amino-acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) that mimics the N-terminal end of SNAP-25 — one of the proteins in the complex that releases acetylcholine at the neuromuscular junction, and the protein botulinum toxin type A cleaves. The idea is competitive interference with that complex, producing less muscle contraction and so fewer expression lines.

It appears on ingredient lists under two INCI names: acetyl hexapeptide-3, the original, and acetyl hexapeptide-8, the current one. They are the same molecule; PubChem files the record under the older name. It is one of the most widely used peptides in cosmetics and is sold in serums at concentrations from a fraction of a percent to around 10%.

How it is thought to work

The proposed mechanism is that the peptide competes with SNAP-25 for a place in the SNARE complex, reducing vesicle fusion and therefore acetylcholine release. That has been shown in cell and tissue systems. Whether a hexapeptide applied to the skin surface reaches motor nerve terminals in meaningful quantity is the unanswered question: peptides of this size cross the stratum corneum poorly, and the trial's modest, short-term roughness changes are equally consistent with an ordinary moisturising effect.

What is still unknown

Whether any effect persists beyond four weeks — no longer trial exists.
Whether the peptide reaches neuromuscular junctions after topical application at cosmetic concentrations.
Whether the single positive trial replicates in an independent centre; the three 2013 papers are one study.

The molecule and how long it lasts

Identity

Formula: C34H60N14O12S
Molecular weight: 889.0 g/mol
CAS number: 616204-22-9
PubChem: CID 11228338
Sequence: Ac-EEMQRR-NH2

Derived from the acetate-salt record; the peptide is the same.

PubChem files the acetate salt record under the former INCI name acetyl hexapeptide-3; the free peptide is CID 71587772

PubChem record, read 29 October 2026; the sequence was derived from that record's own structure and checked against the product label where one exists.

Pharmacokinetics

Route: Topical (cosmetic serum or cream)
Half-life: No human pharmacokinetic study; skin penetration of the intact hexapeptide has not been quantified in people

No pharmacokinetic study in people.

Regulatory status

European Union

Cosmetic ingredient

Lawful in cosmetics. No authorised health claim; a product claiming to treat wrinkles as a medical effect would be making a medicinal claim.

United States

Cosmetic ingredient

Sold in cosmetics without pre-market approval. Not an approved drug and not a recognised compounding substance.

United Kingdom

Cosmetic ingredient

Lawful in cosmetics under the UK Cosmetics Regulation.

Australia

Cosmetic ingredient

Topical cosmetic use is not regulated as a medicine.

Canada

Cosmetic ingredient

Permitted in cosmetics; subject to cosmetic notification.

Sport (WADA)

Not named

Not on the Prohibited List; a topical cosmetic raises no doping question.

Questions people actually ask

Does argireline actually work on wrinkles?

One 60-person randomised trial over four weeks found measurable reductions in skin roughness around the eyes and no change on placebo. That is genuine randomised evidence and it is also the whole of it — one short trial from one centre, published three times. "Possibly a small effect" is as far as the data goes.

Is argireline like Botox?

It targets the same protein complex in laboratory systems, which is where the comparison comes from. No trial has compared the two, and a serum applied to the skin surface is not doing what an injection into a muscle does.

Are acetyl hexapeptide-3 and acetyl hexapeptide-8 different?

No. Same peptide, two INCI names — the ingredient was renamed, and both names are still in circulation on labels and in databases.

One page per claimed effect

CDoes Argireline help with periorbital wrinkles and skin roughness?1 RCT (n=60, 4 wk)
CDoes Argireline help with subjective wrinkle improvement?1 RCT (n=60, 4 wk)
DDoes Argireline help with comparison with botulinum toxin?None
CHow common is safety with Argireline?1 RCT (n=60)

References

1
Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study.Am J Clin Dermatol, 2013;14:147–15360 subjects, randomised 3:1, 4 weeks, twice-daily periorbital application.
2
Duplicate publications of the same 60-subject study.2013The same dataset also appears as PMID 23464592 and PMID 23607739. One study, three papers — counting them separately overstates the evidence threefold.
3
PubChem compound record: acetyl hexapeptide-3 (argireline).PubChem, read 29 Oct 2026Formula, molecular weight, CAS and the sequence used on this page.

Change log

2026-10-29Initial publication. Grade C on one small randomised trial; the triple publication of that trial is recorded in the references.